Stockwinners Market Radar for August 18, 2020 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

19:57 EDT GFL Environmental up 1.9% afterhours following Goldman Sachs upgrade to Buy

19:27 EDT Gilead receives CRL for filgotinib from FDA - Gilead Sciences, Inc. announced that the U.S. Food and Drug Administration has issued a complete response letter for the New Drug Application for filgotinib, an investigational treatment for moderately to severely active rheumatoid arthritis. The FDA has requested data from the MANTA and MANTA-RAy studies before completing its review of the NDA. The MANTA and MANTA-RAy studies are designed to assess whether filgotinib has an impact on sperm parameters. The FDA also has expressed concerns regarding the overall benefit/risk profile of the filgotinib 200 mg dose. "We are disappointed in this outcome and will evaluate the points raised in the CRL for discussion with the FDA. We continue to believe in the benefit/risk profile of filgotinib in RA, which has been demonstrated in the FINCH Phase 3 clinical program," said Merdad Parsey, MD, PhD, Chief Medical Officer, Gilead Sciences.

19:16 EDT Juul Labs' PMTA filed by FDA for substantive review - Juul Labs announced that it received notice from the Food and Drug Administration that the company's Premarket Tobacco Product Applications will enter the substantive review phase. Last month, Juul Labs submitted PMTAs to the FDA for the company's JUUL System - an electronic nicotine delivery system product. The company's submission includes comprehensive scientific evidence for the JUUL Device and JUULpods in Virginia Tobacco and Menthol flavors at nicotine concentrations of 5.0% and 3.0%, as well as information on data-driven measures to address underage use of the company's products. The FDA will now begin a substantive scientific review of the applications. Joe Murillo, Chief Regulatory Officer at Juul Labs said: "We will continue to follow the PMTA process and look forward to this next step as the FDA commences substantive review of the application." The Fly notes that Juul is 35% owned by Altria Group.

18:43 EDT Rio Tinto lowers copper output target on restart delay at Kennecott - The company states: "Rio Tinto's Kennecott mine in Utah has experienced delays to the restart of the smelter due to unexpected issues that appeared following planned maintenance. We are working closely with our customers to limit any disruptions and expect to have the smelter fully operational in two months. As a result, Rio Tinto group production guidance for refined copper in 2020 is now 135-175 kt vs. 165-205 kt previously."

18:11 EDT Spark Energy authorizes share buyback of up to $20M of Class A common stock - Spark Energy announced that its board of directors has authorized a share buyback program of up to $20M of Spark's Class A common stock, par value $0.01 per share through August 18, 2021. The company intends to fund the program through available cash balances and borrowings under its Senior Credit Facility, as well as future operating cash flows.

17:57 EDT Fox Corp CEO buys 229K shares of common stock - In a regulatory filing, Fox Corp disclosed that its CEO Lachlan Murdoch bought 229K share of common stock on August 15th in a total transaction size of $5.9M.

17:45 EDT United Airlines doubles service between San Francisco and Shanghai - United Airlines announced it will increase service to China from two to four weekly flights between San Francisco and Shanghai's Pudong International Airport via Seoul's Incheon International Airport. Beginning Sept.4, 2020, United will operate four weekly flights with Boeing 777-300ER aircraft from San Francisco to Shanghai on Wednesdays, Fridays, Saturdays and Sundays. Customers traveling from Shanghai will return to San Francisco on Mondays, Thursdays, Saturdays and Sundays. Tickets will be available for purchase beginning Wednesday, Aug.19 on united.com and the United mobile app. "United has served mainland China for more than three decades and we look forward to continuing to connect customers traveling between the U.S. and Shanghai with two additional flights beginning in September," said Patrick Quayle, United's vice president of International Network and Alliances.

17:40 EDT Jack Henry falls 9% to $179 after FY21 guidance trails estimates

17:28 EDT Sorrento Therapeutics drops 16% to $10.29 after CFO terminated

17:16 EDT Invitation Homes CEO sells 80K shares of common stock - In a regulatory filing, Invitation Homes disclosed that its CEO Dallas Tanner sold 80K share of common stock on August 17th in a total transaction size of $2.4M.

17:00 EDT Alcon cannot estimate FY20 due to COVID-19 - The company states: "Due to the uncertain scope and duration of the ongoing COVID-19 outbreak, the company is unable to provide an estimate for financial results for the full year 2020. The company is actively managing working capital, cash flow and expenses and prioritizing capital allocation needs. In addition, the company is focused on inventory management and preparing its commercial programs to support the market recovery."

16:55 EDT Extra Space Storage Chairman Kenneth Woolley sells over $10M in shares - Extra Space Storage Chairman Kenneth Woolley disclosed in a filing that he had sold 97,163 shares of company stock at $104.28 per share on June 5. The total transaction value of the sale was $10,132,265

16:46 EDT APi Group chief learning officer Grunau acquires 70,000 common shares - In a regulatory filing, APi Group chief learning officer Paul W. Grunau disclosed the acquisition of 70,000 common shares of the company on August 14 at a price of $14.74 per share.

16:35 EDT Eaton's Fearon sells 50,000 ordinary shares - In a regulatory filing, Eaton Corp.'s Richard H. Fearon disclosed the sale of 50,000 ordinary shares of the company on August 17 at a price of $101.98 per share.

16:33 EDT Goldman Sachs enters into settlement agreement with Malaysia, 1MDB - In a regulatory filing, Goldman Sachs said that on August 18, 2020, it entered into a Settlement Agreement with the Government of Malaysia and 1Malaysia Development Berhad that implements the prior agreement in principle among the parties, which was previously disclosed on the firm's Form 8-K, dated July 24, 2020.

16:31 EDT American Financial Group raises annual dividend 11% to $2.00 per share - The increased dividend, when declared, will be paid on a quarterly basis of 50c per share of common stock beginning in October.

16:18 EDT La-Z-Boy reinstates quarterly dividend of 7c per share - The board elected to reinstate a regular quarterly dividend to shareholders of $0.07 per share, 50% of the dividend amount paid quarterly prior to the company's suspension of dividends as part of its COVID-19 Action Plan. The dividend will be paid on September 15, 2020, to shareholders of record as of September 3, 2020.

16:17 EDT GFL Environmental says Spruce Point report 'baseless, without merit' - GFL Environmental commented on the misleading and false statements reported earlier by Spruce Point Capital Management relating to GFL's management and its financial and business practices. The report contains numerous inaccuracies and mischaracterizations, which GFL believes are solely intended to benefit Spruce Point, who has disclosed that it stands to profit significantly in the event that the stock price of GFL declines. "We are very disappointed by the baseless report put out today by Spruce Point Capital," said Dino Chiesa, lead independent director of the board of GFL. "Spruce Point has never engaged with the company and the report is without merit. We have the support of our shareholders and the utmost confidence in management, who have held themselves to the highest ethical standards. We continue to believe in the strategy of the business and its focus on creating long-term shareholder value."

16:16 EDT Accelerate Diagnostics announces FDA EUA for COVID-19 antibody testing system - Accelerate Diagnostics and BioCheck, a privately-held San Francisco-based company focused on in vitro diagnostics, announced that the FDA has issued an Emergency Use Authorization,. or EUA, for the BioCheck SARS-CoV-2 IgM and IgG Combo Test and fully-automated MS-Fast instrument. In accordance with the previously disclosed commercial supply and collaboration agreement, Accelerate Diagnostics will market, commercialize, and support this serology-based testing platform. The MS-Fast system and BioCheck SARS-CoV-2 chemiluminescence tests are capable of processing human serum samples in 30 minutes to detect antibodies that indicate recent or prior COVID-19 infection.

16:13 EDT Agilent slips 2.3% after Q3 results

16:11 EDT Aeglea BioTherapeutics to present at World Orphan Drug Congress USA 2020 - Aeglea BioTherapeutics announced it will participate in two presentations at the World Orphan Drug Congress USA 2020 being held virtually August 24-27. Presentation Details: Panel Title: Stronger Together: Continuing industry and patient partnerships to ensure inclusion of patient voice along the full continuum of development, from pre-clinical through commercialization.

16:07 EDT LPL Financial closes E.K. Riley asset acquisition - LPL Financial Holdings announced the closing of its acquisition of assets of E.K. Riley Investments,, a broker-dealer and registered investment advisor based in Seattle. E.K. Riley Investments serves more than $2 billion of client assets, which are expected to onboard to LPL's platform by the end of 2020. Approximately 90 percent of the firm's 35 independent advisors are expected to join LPL. "It is a privilege and honor to welcome the E.K. Riley team to LPL. An established and successful firm, E.K. Riley recognized the value that a partnership with LPL could bring to their firm today as well as into the future. One way we demonstrate our commitment to our advisors is through the delivery of relevant resources and technology that help them thrive in today's competitive environment. And with our scale and unwavering advisor focus, our clients can be assured they have a partner who will invest in their success over the long run," said Rich Steinmeier, LPL Financial managing director and divisional president, Business Development. "We are excited to connect the E.K. Riley team to the business solutions, technology and personalized service and support that can help them drive efficiency into their practices and deliver an enhanced experience to their clients. We look forward to being their committed partner for many, many years to come." "Our partnership with LPL is the result of overall cultural similarities between our organizations," said Brian Bertsch, President of E.K. Riley. "We continue to be consistently impressed with their people-centric culture. We are excited to see our advisors thrive as part of the LPL family." Edward Riley, Chairman and CEO of E.K. Riley, agreed: "LPL's culture, technology, and other capabilities allow our financial advisors to offer outstanding service and advice to their clients." The transaction was structured as an asset purchase, and closed on August 18, 2020. LPL continues to anticipate a transaction multiple of ~6x post-synergy EBITDA

16:03 EDT AT&T announces additional early repayment of $1.2B in debt - AT&T has issued notices for the redemption in full of all the outstanding principal amount of three series of bonds totaling approximately $1.2B. When completed, the company will have refinanced or repaid $19.4B of near-term debt obligations since the end of the second quarter through make-whole redemptions, tender offers and repayment of scheduled maturities. Of this amount, $8.2B will reduce the company's debt maturing within one year.

16:02 EDT AT&T announces additional early repayment of $1.2B in deb - AT&T has issued notices for the redemption in full of all the outstanding principal amount of three series of bonds totaling approximately $1.2B. When completed, the company will have refinanced or repaid $19.4B of near-term debt obligations since the end of the second quarter through make-whole redemptions, tender offers and repayment of scheduled maturities. Of this amount, $8.2 billion will reduce the company's debt maturing within one year.

15:58 EDT FDA posts approval of Mylan generic of Biogen's Tecfidera - The FDA on its website posted approval of Mylan's (MYL) generic version of Biogen's (BIIB) multiple sclerosis drug Tecfidera. The approval for Mylan to sell dimethyl fumarate, the active ingredient in Tecfidera, was granted Monday, according to the FDA's Orange Book, Bloomberg notes. Reference Link

15:21 EDT Idex Corp. COO Ashleman sells 8,101 common shares - In a regulatory filing, Idex Corp. president and COO Eric D. Ashleman disclosed the sale of 8,101 common shares of the company on August 14 at a price of $176.1062 per share.

15:06 EDT Change Healthcare acquires Nucleus.io - Change Healthcare announced the acquisition of Nucleus.io, a developer of advanced, fully enabled, cloud-native imaging and workflow technology. Nucleus.io expands Change Healthcare's addressable market by leveraging the over 7,500 organizations Nucleus.io currently serves.

14:01 EDT Toyota launches all-new car leasing, subscription program in India - Toyota Kirloskar Motor announced the launch of its all-new car leasing & subscription program in India through a new vertical, Toyota's Mobility Service that will spearhead TKM's future mobility initiatives in India. To start with, Toyota's Mobility Service will provide leasing and subscription to customers in cities like Delhi-NCR, Bangalore and Mumbai & gradually expand it to ten more cities within the first year. To start with, TKM will partner with existing Brand "KINTO" under Toyota Financial Services, ALD Automotive India & SMAS Auto Leasing India Pvt Ltd. Under this new initiative, customers can pick cars of their choice for a tenure of three to five years on a fixed monthly fee on lease. The monthly fee will be inclusive of vehicle maintenance, insurance and roadside assistance. For subscription, customers will have the flexibility to opt for short-term usage of 24 months to 48 months. Car leasing & subscription gives the convenience of ownership with added flexibilities. It also gives the customer to choose from a variety of products that TKM offers in India, including the Glanza, Yaris, Innova Crysta, Fortuner and the soon to be launched, Urban Cruiser. Reference Link

13:50 EDT Oil-Dri issued patent in Europe for antibiotic-free animal protein production - Oil-Dri Corporation of America announces that the European Patent Office has issued Patent EP 2906238. The patent covers the unique formulation of two existing mineral-based natural feed additives, Varium for poultry and NeoPrime for swine, that are helping global animal protein producers thrive in an era of antibiotic-free production. This patent will be validated in Belgium, France, Germany, Great Britain, Hungary, Italy, Poland, Portugal, Spain and Turkey, bringing the total number of countries to 12 that have issued patent protection for the mineral-based formula. Earlier this year, the United States Patent and Trademark Office issued a patent for the formulations featured in Varium and NeoPrime. China issued a similar patent in 2018. The EU patent provides a methodology for using a natural, mineral-based formula to mitigate the effects of exposure to pathogenic bacteria and the disease-causing toxins they produce, which damage gut health and function. Advancements in natural feed additives are helping to transform animal protein production by providing proven and reliable alternatives to in-feed antibiotics used to promote growth and productivity.

13:26 EDT NY DFS files chargesTeva, Allergan having to do with probe into opiod crisis - Governor Andrew M. Cuomo announced the New York State Department of Financial Services has filed charges and initiated administrative proceedings against Teva Pharmaceutical (TEVA) and its subsidiaries and against Allergan (AABV) subsidiary Allergan Finance. These charges are the third set to be filed in DFS's ongoing investigation into the entities that created and perpetuated the opioid crisis. Teva has been a prolific manufacturer of opioids in the United States, manufacturing approximately 20% of the opioid products that flooded New York from 2006 to 2014. Teva manufactured both its own branded opioids as well as generic opioids through its Actavis subsidiaries. Allergan also manufactured opioid products from 2006 to 2014. "New York will continue to aggressively investigate the bad actors that caused the opioid crisis - an American tragedy that has taken too many lives and caused irrevocable harm to communities in our state and across the country," Governor Cuomo said. "Everyone who has been affected by opioids deserves justice and we will make every effort to deliver it to them by pursuing the companies that defraud the public and holding them accountable to the fullest extent of the law." The DFS Statement of Charges alleges that, like other opioid manufacturers, Teva and Allergan each knowingly furthered false narratives to legitimize dangerously powerful opioid products as appropriate for a broad spectrum of pain. In particular, the companies' messaging greatly downplayed the drugs' long-known addictive nature and risks. This strategic effort by the opioid industry caused an increased acceptance of opioids as medically legitimate, necessary, and appropriate painkillers by both patients and medical professionals. As a result, demand for opioids soared to unprecedented levels as did the predictable crisis of addiction and abuse that resulted from this overprescribing. Reference Link

13:13 EDT Oculus users will need Facebook account to use future headsets - Facebook's Oculus announced a number of updates on how people log into Oculus devices, while still keeping their VR profile. Starting in October 2020: Everyone using an Oculus device for the first time will need to log in with a Facebook account; Existing users who already have an Oculus account will have the option to log in with Facebook and merge their Oculus and Facebook accounts; Existing users and who choose not to merge accounts can continue using their Oculus account for two years. "After January 1, 2023, we will end support for Oculus accounts," the company said. "If you choose not to merge your accounts at that time, you can continue using your device, but full functionality will require a Facebook account. We will take steps to allow you to keep using content you have purchased, though we expect some games and apps may no longer work. This could be because they include features that require a Facebook account or because a developer has chosen to no longer support the app or game you purchased. All future unreleased Oculus devices will require a Facebook account, even if you already have an Oculus account." Reference Link

12:53 EDT M.D.C. Holdings CFO Martin Robert Nathaniel sells 20K shares of company stock - M.D.C. Holdings CFO Martin Robert Nathaniel disclosed in a filing that he had sold 20,000 shares of company stock on August 17 at $46.11 per share for a total sale amount of $922,200.

12:44 EDT Evertec jumps 10% after Bloomberg says exploring potential sale - Shares of Puerto Rico-based payments processor Evertec (EVTC) jumped after Ed Hammond and Nabila Ahmed of Bloomberg reported that the company is exploring strategic options including a potential sale. The company is working with a financial adviser to field interest from potential buyers, people familiar with the matter told Bloomberg. Evertec could be attractive to larger payments companies such as Global Payments (GPN) and Fiserv (FISV), sources said. Shares of Evertec are up 10%, or $3.23, to $34.40 following the report.

12:26 EDT Eastman Kodak rallies 67% to $12.77 as trading resumes

12:19 EDT Kodak trading resumes

12:14 EDT Kodak trading halted, volatility trading pause

11:56 EDT Planet Fitness CEO says 1,500 of 2,000 gyms are now open - Chris Rondeau is speaking on CNBC.

10:58 EDT Co-Diagnostics COVID-19 test partner selected by Los Angeles Unified schools - Los Angeles Unified Superintendent Austin Beutner announced over the weekend that Clinical Reference Laboratory will provide the school district with COVID-19 testing specimen collection kits and process the tests in its lab in Lenexa, Kansas. Co-Diagnostics (CODX) announced on August 3 that its partner, Clinical Reference Laboratory, received FDA Emergency Use Authorization for CRL Rapid Response, a saliva-based COVID-19 test that can be self-administered and then tested using Co-Diagnostics' CoPrimer technology. Reference Link

10:35 EDT Justice Department files False Claims Act against Teva Pharmaceuticals - The U.S. Attorney's Office has filed a complaint under the False Claims Act against Teva Pharmaceuticals USA. and Teva Neuroscience, the maker of Copaxone, a drug for multiple sclerosis. The government alleges that Teva conspired with a specialty pharmacy, Advanced Care Scripts, and two purportedly independent foundations, Chronic Disease Fund and The Assistance Fund, to violate the Anti-Kickback Statute and False Claims Act by using the foundations as conduits to subsidize Medicare co-pays for Copaxone, all while steadily raising Copaxone's price, the Justice Department said in a statement. The government alleges that, from 2006 through at least 2015, Teva paid the two foundations well over $300M with the intent and understanding that the foundations would use Teva's money to cover the Medicare co-pays of patients taking Copaxone. During the same period, Teva raised the price of Copaxone from approximately $17,000 per year to over $73,000 per year, according to the DOJ. Shares of Teva are down 2% to $11.34 in morning trading. Reference Link

10:28 EDT Sify regains compliance with Nasdaq minimum bid price requirement - Sify Technologies announced receiving a letter from NASDAQ confirming that it has regained compliance with the minimum bid price rules. On April 23, 2020, NASDAQ had notified the Company that its common stock failed to maintain a minimum bid price of $1.00 over the previous 30 consecutive business days as required by the Listing Rules of The NASDAQ Stock Market. Further, NASDAQ, in the said communication, had provided the company a compliance period of 180 calendar days in which to gain compliance. The letter also states that if at any time during this tolling period or 180 day period the closing bid price of the Company's security is at least $1 for a minimum of ten consecutive business days, Nasdaq will provide a written confirmation of compliance and the matter will be closed. Since then, NASDAQ has determined that for the last 10 consecutive business days, from July 30 to August 12, 2020, the closing bid price of the Company's common stock has been at $1.00 per share or greater. In a letter dated August 13, 2020, NASDAQ notified Sify has regained compliance with Listing Rule 5550(a)(2) of the Minimum Bid price rule.

10:17 EDT Teva drops following reports of U.S. lawsuit over false Medicare claims - Shares of Teva Pharmaceutical Industries after both Reuters and Bloomberg reported that the U.S. government sued the company for making false Medicare claims. In a lawsuit filing, the government claims Teva violated the anti-kickback law and paid over $300M for Copaxone co-pays, Bloomberg reports. Shares of Teva are down 3% to $11.25 in morning trading.

10:04 EDT NPW completes acquisition of Auto Plus assets in Washington, Oregon - National Auto Parts Warehouse and Icahn Automotive Group announced they have completed NPW's acquisition of substantially all Auto Plus assets in Washington state and Oregon. The transaction includes two Pep Boys Parts retail store locations in Seattle, Washington, and excludes Pep Boys automotive service centers. National Auto Parts Warehouse will convert and rebrand the acquired Auto Plus and Pep Boys Parts retail locations as Auto Value parts stores. Icahn Automotive will continue to own and operate all of its service centers under the Pep Boys brand in Washington state and Oregon and focus on serving the growing demands of do-it-for-me customers and rapidly growing fleets.

10:00 EDT Avangrid Renewables, PSE announce power purchase agreement - Puget Sound Energy and Avangrid Renewables, a subsidiary of AVANGRID, Inc., announced an agreement that will be supplied by a new 200 megawatt wind farm, enough energy to power over 60,000 homes on an annual basis. The wind farm will be built by Avangrid Renewables in Sherman County, Oregon. The Golden Hills Wind Farm will be Avangrid Renewables' 13th in the Pacific Northwest and an important step toward realizing the company's nearly 19 gigawatt project pipeline. The project will help PSE meet its goals to reduce carbon dioxide emissions while providing additional capacity to serve customers, particularly during winter periods of high electricity demand.

09:56 EDT Uber says $24.99 monthly membership now live in U.S. cities - Uber Technologies announced that Uber Pass is now live nationwide for U.S. customers in cities like Hartford and New Haven, Columbus, Honolulu, Madison, Milwaukee, Nashville, New York City, Portland, Seattle, St. Louis, and more. The monthly membership "unlocks savings on every ride, Eats delivery, and grocery order through an all-in-one bundle of benefits," Uber said in a statement. At $24.99 per month, Uber Pass provides 10% off UberX, XL and Comfort rides; 15% off Black, SUV and Premier rides; $0 delivery on Eats orders over $15; 5% off Eats deliveries over $15; $0 delivery on grocery orders over $40, where available. Reference Link

09:47 EDT Huami falls -9.2% - Huami is down -9.2%, or -$1.34 to $13.28.

09:47 EDT Kohl's falls -12.1% - Kohl's is down -12.1%, or -$2.84 to $20.61.

09:47 EDT Sea Limited rises 10.0% - Sea Limited is up 10.0%, or $13.44 to $147.72.

09:44 EDT Home Depot says 'notable strength' in low spend Pro in Q2 - Says saw "great engagement" from both Pro and DIY customers in Q2. Says "super pleased" with both cohorts.

09:33 EDT GFL Environmental drops 6% to $19.90 after Spruce Point short report

09:29 EDT Groupon announces Rezdy as inaugural Groupon Connect partner - Groupon announced the first successful integration to the company's recently launched next-generation API, Groupon Connect, that enables leading booking partners, reservation and ticketing platforms to directly connect their merchants to the Groupon platform. Rezdy is the first partner to successfully integrate to Groupon Connect, providing tour and other attractions operators with more control over their promotions by giving them the ability to sync their existing Rezdy booking capabilities with Groupon inventory.

09:21 EDT Mnuchin says 'there's a deal to do' if Democrats 'want to be reasonable' - Treasury Secretary Steven Mnuchin is speaking on CNBC.

09:19 EDT Mnuchin offers no comment on potential Oracle bid for TikTok - Treasury Secretary Steven Mnuchin is speaking on CNBC.

09:17 EDT Kohl's to close stores on Thanksgiving Day

09:16 EDT Kohl's: Holiday season will be 'like no other'

09:15 EDT Mnuchin says Pelosi, Schumer 'not willing to strike reasonable deal' - Treasury Secretary Steven Mnuchin is speaking on CNBC.

09:14 EDT Premier, AstraZeneca partner to reduce hospitalization in Hyperkalemia patients - Premier (PINC) announced it has reached a milestone in its partnership with AstraZeneca (AZN). Premier Applied Sciences has implemented evidence-based care practices with nearly 370 hospitals across the U.S. designed to prevent patients with hyperkalemia from requiring treatment in the acute-care setting. The risk of hyperkalemia increases significantly for patients with chronic kidney disease and for those who take common medications for heart failure, such as RAAS inhibitors, which can increase potassium in the blood. Hyperkalemia occurs in 23%-47% of patients with chronic kidney disease and/or heart failure. Hyperkalemia can lead to hospitalization and increased resource utilization. Together, Premier Applied Sciences and AstraZeneca have developed a protocol for monitoring and treating patients with hyperkalemia. The protocol includes the potential use of Lokelma, a potassium binder indicated for the treatment of hyperkalemia in adults. As part of the first phase in Premier's partnership with AstraZeneca, Premier Applied Sciences conducted a study to examine the clinical characteristics of patients with hyperkalemia and assessed hyperkalemia-related readmissions, emergency room presentations, outpatient visits and costs. For the second phase of the study, Premier will utilize a linked sample from the Premier Healthcare Database and a large commercial claims database to further assess the association between Lokelma use and specific clinical outcomes such as hyperkalemia, cost, readmissions and other hospital visits among patients with hyperkalemia. The final component of this de-identified study will examine the impact of having a hyperkalemia discharge protocol on cost and healthcare resource utilization among hospitalized patients.

09:14 EDT Kohl's pursuing opportunities to capture dislocated sales from closures - Kohl's is pursuing opportunities to capture dislocated sales from closures and competitors, the company said on its earnings call.

09:12 EDT Kohl's: Worst retail environment in nearly 60-year history - Comments taken from Q2 earnings conference call.

09:11 EDT Generex, Bintai Kinden sign agreement for coronavirus vaccine for Malaysia - Generex Biotechnology announced that the company has signed a memorandum of understanding with Bintai Kinden Corporation of Malaysia for the development and commercialization of the Ii-Key-SARS-CoV-2 coronavirus vaccine. The Ii-Key-SARS-CoV-2 vaccine is designed as a "Complete Vaccine" that has the potential to induce the T-Cell and antibody immune responses that can provide protective immunity with long-lasting immunologic memory against SARS-CoV-2 in a highly specific manner to ensure safety. With this agreement, Bintai has agreed to pay Generex up-front development fees and back-end licensing payments, and will pay 100% of the funding required for the commercial development of the Ii-Key-CoV-2 vaccine including laboratory work, manufacturing, regulatory filings and the clinical development program for regulatory approval of the vaccine in Malaysia. Additionally, upon approval of the Ii-Key-CoV-2 vaccine in Malaysia, Generex will earn royalties on sales of the vaccine with potential revenues of up to $150M. Under terms of the agreement, Generex and Bintai have agreed to collaborate and have developed a strategy towards the rapid development of the Ii-Key-CoV-2 vaccine with three primary goals: 1. Streamline the Vaccine Development Process: The development program will simultaneously implement different stages of development and production, so the vaccine can be developed at a faster rate. 2. Conduct Clinical Trials Globally: Generex and Bintai agree that the development of a vaccine for COVID-19 should not be a race for high income countries, so clinical trials will be conducted in as many countries as possible to enable the best chance of finding a vaccine that is safe, effective and affordable for everyone. This multi-country approach will ensure that the efficacy of the vaccine is generalizable or suited to the native population and to further obtain commercial license for sale of Ii-Key-SARS-CoV-2 Peptide Vaccine from the Malaysia Ministry of Health and other health authorities around the world. 3. Build Global Manufacturing Capacity: Bintai and Generex agree that the vaccine manufacturing should serve not only as an essential element of a vaccination program for each country, but also as an economic stimulus, as many countries shift their focus to rebuild their economies following the inevitable economic shutdown as the battle of the global pandemic continues. The legal contracts for the licensing and development agreements, currently being mutually drafted by the Generex and Bintai legal teams, are expected to be finalized and signed in the coming days. Generex will file an 8K report with the SEC upon signing of the official contract.

09:09 EDT Oxford Industries appoints Milford McGuirt to board of directors - Oxford Industries announced the appointment of Milford McGuirt to the Company's Board of Directors. Mr. McGuirt retired as Managing Partner of KPMG's Atlanta Office and Mid-South Region.

09:08 EDT Yelp announces new hiring experience through Request-A-Quote product - Yelp is building on its Request-A-Quote product by evolving it into an end-to-end hiring experience for home, local, automotive and professional services. As part of the new hiring experience, Yelp is expanding and revamping new guided questionnaires for Request-A-Quote to an additional 100 business categories in the coming months to help better match the right professionals with the most relevant projects, as well as giving consumers and businesses a way to schedule appointments right from the Yelp platform. Yelp is also introducing Nearby Jobs, a new paid product that gives professionals an way to proactively grow their business and get in front of more people looking to hire pros like them. The new experience is part of Yelp's new design.

09:06 EDT Flowers Foods appoints three new independent directors - Flowers Foods announced that its board of directors elected three new independent directors effective August 14 expanding the board from eight to 11 members: Edward J. Casey, CEO officer of IDEMIA Identity & Security NA; and Thomas C. Chubb, chairman, CEO and president of Oxford Industries; and Terry S. Thomas, executive vice president, chief customer officer US of the Unilever Group. Ed Casey has served as CEO of the North American business for IDEMIA, a global leader in identity and digital security technologies, since 2018. Previously, he served as acting CEO, COO, and a member of the board of Serco Group, a provider of public services in defense, transportation, immigration, healthcare, and other sectors based in the United Kingdom, and served as chairman CEO officer of Serco's North American business. Tom Chubb has served as chairman, CEO and president of Oxford Industries, a publicly held, lifestyle apparel company with a brand portfolio that includes Tommy Bahama, Lilly Pulitzer, Southern Tide, The Beaufort Bonnet Company, and Duck Head, since 2015. During the course of his career with Oxford Industries, which spans more than 30 years, he was named vice president, general counsel, and secretary in 1999; executive vice president in 2004. Terry Thomas has served as executive vice president, chief customer officer US for the Unilever Group, a global food, personal care, and household products company, since 2019.

09:06 EDT ToughBuilt expands on Lowe's Canada website - ToughBuilt Industries (TBLT) announced their products will be available on www.lowes.ca. (LOW). Lowes.ca will carry a wide array of ToughBuilt products, including but not limited to Cliptech tool belts, bags and totes, knee pads, sawhorses, and Miter Saw Stands. Lowe's Canadian customers will now have the option to purchase ToughBuilt products while they shop online at www.lowes.ca.

09:03 EDT LPL Financial partners with Slack for messaging capabilities - LPL Financial (LPLA) announced that the firm has partnered with Slack (WORK) to give advisors and their teams new tools to communicate in real time, whether working from the same office, from home or on the road. Slack allows teams to communicate faster than with traditional email, and provides the ability to save conversations and pick up right where they left off, supporting productivity and collaboration while being able to locate information quicker.

09:02 EDT AssetMark Financial launches eService team, expands digital servicing tools - AssetMark announced its new dedicated eService team to help financial advisors meet the increasing demand for digital servicing during the pandemic while reinforcing the firm's commitment to fostering deep relationships with its advisors. The new personal, online assistance offered through the eService team is an extension of the firm's industry-leading service offering that scales with the growing needs of today's investors and their financial advisors. AssetMark eService provides fast, personalized, digital response service levels to client outreach between 8 a.m. and 8 p.m. ET. The new service builds upon the firm's digital servicing tools aimed at further increasing efficiencies for advisor practices, which include: eDelivery: Lets advisors and investors minimize mail delays and limit potential identity theft with electronic delivery of reports and documents; eSignature: Delivers a 100% digital account opening experience for qualifying accounts; eLearning: Planned online videos and guides to help advisors quickly navigate and maximize services available on the platform to streamline administrative tasks and enhance client services

08:56 EDT McEwen Mining announces flow-through financing - McEwen Mining announced a strategic financing to continue the exploration program at properties in the Timmins region of Ontario. The financing consists of a $9,912,500 bought deal private placement offering of 6,000,000 flow-through common shares priced at $1.65 per flow-through common share led by Cantor Fitzgerald Canada Corporation as sole bookrunner, and includes Roth Capital Partners, Red Cloud Securities Inc., and Maison Placements Canada Inc. The Offering Price represents a premium of 21% over the closing price of McEwen common shares on the TSX as of August 17, 2020. The Offering is expected to close on or before September 10, 2020 and is subject to customary closing conditions, including approval from the TSX and NYSE. The proceeds of this Offering will be used exclusively for generative exploration activities on McEwen's properties in the Timmins region.

08:50 EDT Resonant announces 5G XBAR filters manufactured using SAW process - Resonant has announced that its patented 5G XBAR filters, for non-mobile applications have been successfully manufactured by two different foundry partners using a standard surface acoustic wave front end process. Resonant's unique ability to manufacture a complex 5G filter on a SAW front end process was made possible by the company's EDA multi-physics platform, Infinite Synthesized Networks. Both partners manufactured Resonant's XBAR filter, which was designed for the non-mobile n79 5G band, which pertains to applications such as infrastructure, WiFi CPE and automotive, among others. To date, six separate foundries have now successfully manufactured Resonant's XBAR filters. Resonant's XBAR filters have previously been manufactured on a MEMs process line, as utilized by Resonant's industry-leading partner Teledyne. The collaboration with Teledyne continues as we expand the capabilities of the non-mobile XBAR technology. The n79 band XBAR filters manufactured demonstrate minimum insertion loss of less than1 dB, 600 MHz bandwidth from 4400-5000 MHz bandwidth, and high rejection, resulting in superior full bandwidth performance, maximizing data speed by minimizing signal loss and interference, an additional benefit being longer battery life. The partners that manufactured the n79 band XBAR filters were both part of the Resonant Foundry Program, and the results closely mirrored the simulations performed in Resonant's proprietary ISN software platform.

08:44 EDT Apple announces Apple Music Radio, launches two additional stations - Apple announced two new live global radio offerings on Apple Music, now available to music fans in 165 countries. Beginning immediately, Beats 1 will be renamed Apple Music 1 and two additional radio stations will launch: Apple Music Hits, celebrating songs from the '80s, '90s, and 2000s, and Apple Music Country, spotlighting country music. Since Apple Music's launch in 2015,

08:42 EDT BlueCity releases ESG, CSR reports - BlueCity Holdings released its 2019 Environmental, Social and Governance report and 2019 Corporate Social Responsibility Report, both in their very first editions, which highlight the Company's initiatives to drive progress towards a more diverse and inclusive space for its employees, its 49 million users globally and wider society. HIV prevention: The Blued app facilitated about 50,000 online appointments for HIV testing at more than 200 partnered testing establishments in China as of 2019; 12,304 hours of staff voluntary service were dedicated to HIV-prevention; Over 10 million page views for HIV-prevention content on BlueCity's platforms. R&D and privacy protection: The company invested RMB 130M in research and development during 2019 with a dedicated team of 130 people, accounting for 26% of our total staff. Information security and users' privacy is our top priority, which is especially important for the LGBTQ users that we serve. We have invested significant resources in this area and adopted the principle of data minimization, which limits personal data collection, storage, and usage to data that is relevant, adequate, and absolutely necessary for carrying out the purpose for which the data is processed. The company encrypts confidential personal information we gather from our platform and have established strong internal protocols, under which we grant classified access to confidential personal data to a limited number of employees with strictly defined and layered access authority. Content Monitoring and Preventing Use by Minors: Due to the real-time nature of live streaming, a popular feature of the Blued app, BlueCity utilizes a combination of manual screening and AI image recognition technology to promptly remove any inappropriate or illegal content. In 2019, more than 1.47 million pieces of illegal and inappropriate content were removed. The Blued app strictly limits people under the lawful age from using its platform, which is clearly and repeatedly stated in its user terms and conditions, new-user registration page, welcome screen, home page banner, and chat interface. Once a user is determined to be underage, the account concerned will be identified and blocked by the platform. In addition to the information released in the 2019 reports, BlueCity has actively adopted measures to help our community and broader society in the fight against the ongoing COVID-19 crisis globally, including: Organizing #StayProud: A Virtual Pride Experience, Blued's first-ever online pride event in late June to encourage the LGBTQ community to stay strong and proud during these challenging times, with profits of the show donated to the Los Angeles LGBT Center. The partnership with not-for-profit organizations in countries such as South Korea, India, Japan, the Philippines, Vietnam to donate much-needed medical supplies or conduct COVID-19-related training and education. BlueCity was ranked at No. 12 among 50 top Chinese Internet companies for its CSR performance in 2019 according to a latest report released last month by China CSR Research Center, an affiliate of Southern Weekly, one of the country's most influential media outlets.

08:39 EDT Eros International CEO Robert Simonds comments on recently completed STX merger - Eros STX co-chairman and CEO, Robert Simonds, commented on the recently completed merger between Eros and STX. Simonds stated, "Now that we have begun the integration process, we wanted to take a moment to reach out to all of you as a group to express our tremendous excitement about what this transaction means for us and the incredible opportunities in front of us. From the moment we first began discussing this combination, it was clear to both companies that this transaction could represent far more than a sum of the parts. Each of the companies and respective teams brought compelling insights and experiences to the table, but frankly neither company, on its own, could really move the needle in the global media and entertainment landscape. We believe we are now positioned to create a truly global digital entertainment enterprise. Due to its rapid growth and increasing broadband and internet availability in the market, India has become one of the most important entertainment battlegrounds in the world. You need look no further than Jio's recent nearly $20 billion capital raise, backed by some of the largest US-based technology and venture capital investors, and largely centered on the rollout of 5G throughout the country. Media and entertainment looks to play a critical role in that massive regional growth... When you add STX content to the content running through the Eros Now Prime platform, as well as the ultra-premium co-production content we are producing with some of the largest global players like Amazon and Netflix, we have laid the groundwork for a truly massive opportunity. STX has consistently been leading the innovation in Hollywood to a cost-effective model for both the production and distribution of feature film content. What initially began as an effort to produce feature films at a significantly lower price point, and then to utilize an innovative financing structure to cover approximately 50-70% of the cost of our feature films through a combination of international minimum guarantees and production and tax incentives, has recently expanded to a point where STX has been able to spend dramatically less than its competition in marketing theatrical releases for comparable films. That has meant substantially less risk in each film produced, significantly greater profit potential on each film in success with a far higher return on invested capital for successful films relative to our competitors producing similar movies... We do continue to believe in the value of the theatrical experience. This unique shared viewing experience is still of the utmost importance to the biggest storytellers and stars on the planet and our ability to deliver theatrical films efficiently gives us a significant competitive advantage. While the current pandemic has significantly delayed the release of our Gerard Butler film Greenland in most territories, the performance over the past two weekends in certain international territories has been remarkable, with the film performing at or exceeding most of Gerard's other action films in those territories despite the fact that theaters there are only permitting 50% capacity and limiting the total number of showings each day. While this pandemic continues to impact where consumers are able to see the film and while consumers continue to evaluate how they want to view feature content in the future, we will continue to be able to deliver premium content where, when and how consumers want to enjoy it without fundamentally challenging our business model. Despite the business challenges arising from the pandemic, Eros STX has seen a substantial increase in both new subscriptions and consumer engagement on the Eros Now platform driven by increased time spent at home as well as fewer out-of-home entertainment options available. Eros Now has a strong slate of films and original series scheduled for release over the coming quarters, and the Company expects this to help drive continued growth in the paying subscriber base in India and around the world. Consumers are watching more content on the platform than ever before, an acceleration of growth that will provide strong tailwinds to the combined business for the coming quarters."

08:37 EDT Daseke appoints Brian Bonner as chairman of the board - Daseke announced that Brian Bonner ended his term as Executive Chairman, effective August 14, 2020. Bonner will continue to serve the Company as an Independent Director and Chairman of the Company's Board of Directors, maintaining the responsibilities commensurate with the Chairman position. Bonner has served as an Independent Director since 2015.

08:35 EDT JinkoSolar signs contract with Shanghai Electric - JinkoSolar Holding announced that it has signed a contract with Shanghai Electric to supply approximately 1 GW of solar modules for Phase V of the Dubai Electricity and Water Authority, or DEWA, Solar Park. The DEWA project is located in Dubai, and is part of the government's sustainable development to support the Dubai Clean Energy Strategy 2050 with the goal of providing 75% of Dubai's total power output from clean energy sources by 2050. The innovative, bifacial design and low operating temperature of the modules were chosen to help achieve high power gain, effectively reduce LCOE and improve ROI for the project. At the same time, JinkoSolar reached a strategic partnership agreement with Shanghai Electric based on the long-term cooperation between the two parties.

08:33 EDT Predictive Oncology's Skyline Medical sells 8 STREAMWAY Systems - Predictive Oncology announced that its Skyline Medical division has completed the sale of 8 STREAMWAY systems to a large university hospital organization in Virginia for a new surgical center. The hospital system already has 2 STREAMWAY systems currently in use. The sale is expected to generate approximately 4,000 procedures annually. The company has now sold 13 STREAMWAY systems during Q3 2020.

08:21 EDT Carnival investigating ransomware attack against one of its cruise brands - In a regulatory filing, Carnival said that on August 15, the company detected a ransomware attack that accessed and encrypted a portion of one brand's information technology systems. The unauthorized access also included the download of certain of its data files."Promptly upon its detection of the security event, the Company launched an investigation and notified law enforcement, and engaged legal counsel and other incident response professionals. While the investigation of the incident is ongoing, the Company has implemented a series of containment and remediation measures to address this situation and reinforce the security of its information technology systems. The Company is working with industry-leading cybersecurity firms to immediately respond to the threat, defend the Company's information technology systems, and conduct remediation. Based on its preliminary assessment and on the information currently known, the Company does not believe the incident will have a material impact on its business, operations or financial results. Nonetheless, we expect that the security event included unauthorized access to personal data of guests and employees, which may result in potential claims from guests, employees, shareholders, or regulatory agencies. Although we believe that no other information technology systems of the other Company's brands have been impacted by this incident based upon our investigation to date, there can be no assurance that other information technology systems of the other Company's brands will not be adversely affected."

08:20 EDT Catalyst, KYE announce exclusive license agreement for Firdapse in Canada - Catalyst Pharmaceuticals, and KYE Pharmaceuticals announced that the companies have entered into an exclusive license agreement under which KYE will commercialize Firdapse in Canada. Firdapse is indicated for the symptomatic treatment of Lambert-Eaton myasthenic syndrome in adults. Under the terms of the agreement, Catalyst will supply Firdapse to KYE and KYE will be responsible for promotion, sales, advertisement, marketing, product importation and distribution. KYE will also be responsible for the ongoing maintenance of the regulatory file and future communications with Health Canada.

08:17 EDT HTG Molecular introduces oncology applications, expands analytics capabilities - HTG Molecular Diagnostics announced the commercial release and immediate availability of HTG EdgeSeq Reveal version 3.0, adding additional applications and software functionalities. The HTG EdgeSeq Reveal, launched in January 2019, is a web-based biostatistical analysis software suite designed to accelerate customer research by streamlining their statistical analysis of samples processed with HTG's RUO profiling assays. Today's release adds several applications and additional functionalities, including: RUO oncology applications - Customers globally are now able to leverage RUO oncology applications specifically built upon, and using data from, the HTG EdgeSeq Precision Immuno-Oncology Panel to generate immune, stroma and tumor microenvironment scores to better understand factors such as tumor inflammation and stromal response to a tumor. HTG EdgeSeq Pan B-Cell Lymphoma Panel - Integration of the recently-launched HTG EdgeSeq Pan B-Cell Lymphoma Panel enables customers globally to assess DLBCL Cell of Origin, in addition to using the analytic capabilities of HTG EdgeSeq Reveal to potentially develop molecular subtyping algorithms to classify and research various aggressive lymphomas. RUO menu expansion for Thermo Fisher Scientific Next-Generation Sequencing platform - Expanded profiling assay menu allows customers globally to utilize the analytic capabilities of HTG EdgeSeq Reveal with HTG's entire RUO profiling assay menu, including assays for use with both Illumina, Inc. and Thermo Fisher Scientific NGS platforms.

08:14 EDT CHF Solutions' Aquadex products granted Federal Supply Schedule contract - CHF Solutions announced that its Aquadex product line has been added to the Federal Supply Schedule, expanding access to all federal government agencies, including the Department of Veterans Affairs, Indian Health Services and Department of Defense Medical Treatment Facilities. The Aquadex system has been used at individual VA hospitals for many years. In each case, the company has negotiated contracts with each individual facility. Now, in partnership with Downeast Logistics LLC, the Aquadex SmartFlow console and Aquadex FlexFlow Blood Circuit Set have been added to the federal supply contract between Downeast Logistics and the federal government and is approved for purchase by all facilities, thereby reducing the time associated with approval at each individual facility.

08:13 EDT Walmart moving toward launch of membership service, CEO says

08:10 EDT Bionano Genomics appoints Alka Chaubey as CMO - Bionano Genomics (BNGO) announced that Dr. Alka Chaubey, PhD, FACMG, will join Bionano as its first chief medical officer, effective August 31, 202. As CMO of Bionano, she will take the lead in driving toward our goal of global, widespread adoption of Saphyr for use in various clinical applications, including digital cytogenetics. Chaubey comes to Bionano with almost 20 years of scientific and clinical experience, including at PerkinElmer (PKI), where she currently serves as the Head of Cytogenomics for PerkinElmer Genomics and for Vanadis.

08:08 EDT Walmart's back-to-school sales negatively impacted by COVID-19

08:07 EDT Walmart's July U.S. comps grew more than 4% - Walmart said: "Q2 sales started strong, both in-store and online, particularly in general merchandise, helped by government stimulus spending. Grocery sales had another strong quarter. As stimulus funds tapered off, sales started to normalize, but July comps still grew more than four percent." Comments taken from Q2 earnings conference call.

08:05 EDT Emmaus Life Sciences submits MAA to Saudi Food and Drug Authority - Emmaus Life Sciences announced the submission of an application to the Saudi Food and Drug Authority for Marketing Authorization for Endari in the Kingdom of Saudi Arabia. This follows Emmaus' announcement that the SFDA had granted Endari a priority review designation as part of its program to expedite the review of drugs that are expected to have a significant impact on the treatment of a disease with unmet medical need. Endari, Emmaus' prescription grade L-glutamine oral powder, is approved by the United States FDA and the Israeli Ministry of Health to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older. Endari can currently be prescribed in Saudi Arabia on a named patient basis and will continue to be available on that basis during the review and approval process with the SFDA. Emmaus estimates that there are approximately 225,000 sickle cell disease patients that could potentially be treated with Endari in the Middle East and North Africa region. Saudi Arabia has the highest prevalence of sickle cell disease in the MENA region with an estimated 100,000 treatable patients.

08:04 EDT Agilent invests roughly $150M to add 25,000 square feet to Colorado facility - Agilent announced it will expand its state-of-the-art production facility in Frederick, Colorado, that develops and manufactures "oligos," which are short DNA and RNA molecules used to create nucleic acid-based therapeutics. Oligos hold the potential to be used in developing treatments for cancer, COVID-19, cardiovascular disease, rare and infectious diseases and other conditions. The expansion will more than double the current capacity for manufacturing therapeutic oligos at the Frederick site. Agilent expects the supplier market for therapeutic oligos to exceed $750M in 2025 with projected double-digit annual growth over the next five years. The addition of the higher-volume manufacturing line will help Agilent meet this growing demand from pharmaceutical and biotech companies. Customer shipments from the new line are expected to begin by the end of 2022. Agilent is investing approximately $150M to add 25,000 square feet of manufacturing capacity to the Frederick facility. The new capacity will also expand Agilent's presence in Colorado, where the company has had an oligo manufacturing site in nearby Boulder since 2006. The Frederick facility, 30 miles north of Denver, has been operating since 2019. Both sites are current good manufacturing practices, or cGMP, facilities, as designated by the FDA.

08:03 EDT Harsco appoints Wendy Livingston as SVP, CHRO - Harsco Corporation (HSC) announced it has appointed Wendy Livingston as Senior Vice President, Human Resources and Chief Human Resources Officer. In this role, Livingston will be responsible for developing the human resources global strategy for the Company and its 13,000 employees located in more than 30 countries. She will work alongside corporate functional heads and division presidents on driving performance, teamwork and people development to achieve Harsco's financial objectives and long-term business plan. Livingston joins Harsco from The Boeing Company (BA) where she worked for the past 24 years, most recently as Vice President, Corporate Human Resources.

08:02 EDT EDAP TMS announces two publications highlighting HIFU technology - EDAP TMS announced that two papers highlighting studies of the Company's high intensity focused ultrasound technology for the effective ablation of prostate cancer tissue have been accepted for publication in the prestigious peer-reviewed Journal of Urology, the official journal of the American Urology Association. The two studies, scheduled for publication in the September and October paper editions of the journal, detail clinical outcomes from HIFU procedures conducted at the first two hospitals to purchase the Ablatherm device in the US shortly after the FDA clearance at the end of 2015. Details of the publications are as follows: High Intensity Focused Ultrasound Hemigland Ablation for Prostate Cancer: Initial Outcomes of a United States Series. Andre Abreu et al., USC Institute of Urology, Keck School of Medicine, University of Southern California, Los Angeles, California. This study describes a study of 100 men with a confirmed diagnosis of prostate cancer, 72% of whom were diagnosed with intermediate or high-risk disease. All study subjects underwent hemi-gland ablation with HIFU as primary treatment for prostate cancer between December 2015 and December 2019. Radical treatment was avoided in 91% of men at two years. There were no major complications, and no rectal fistulas occurred. The study found that urinary symptoms returned to near baseline questionnaire scores within 3-6 months and sexual function returned to baseline by 12 months. Prospective Evaluation of Focal High Intensity Focused Ultrasound for Localized Prostate Cancer. B. Nahar et al., Department of Urology, University of Miami Miller School of Medicine, Miami, Florida, Sylvester Comprehensive Cancer Center. This paper describes a single-center prospective study of 52 prostate cancer patients who underwent HIFU treatment between January 2016 and July 2018. Sixty seven percent of study subjects were diagnosed with intermediate or high-risk disease. All patients were treated with EDAP's Ablatherm HIFU device and were followed for a minimum of 12 months post-procedure. Biopsies were performed at 6 or 12 months for high or low/intermediate risk cancers, respectively. Two years post procedure, only one patient had to undergo radical prostatectomy surgery. No change in continence was observed and sexual function returned to baseline at 12 months.

07:47 EDT Marcus Theatres announces next phase of reopening - Marcus Theatres, a division of Marcus, announced the timing for the next two phases of reopening theatres. On Friday, August 21, 35 theatres will reopen and on August 28, another 30+ theatres will welcome guests back. In total, more than two-thirds of the 91 Marcus Theatres or Movie Tavern locations will be reopened in time for the domestic release of the film "Tenet" on September 3. The remaining theatres will open at a later date. All theatres will feature updated health and safety measures.

07:39 EDT Acreage files proxy statement related to amended Canopy Growth arrangement - Acreage Holdings (ACRGF) announce that it: obtained an interim order of the Supreme Court of British Columbia in connection with its proposed amended arrangement involving Canopy Growth Corporation (CGC) to be implemented under a statutory plan of arrangement pursuant to section 288 of the Business Corporations Act; and filed its proxy statement and management information circular and related materials in respect of the special meeting of Acreage shareholders to be held on September 16, 2020 to approve the Amended Arrangement and matters related thereto. Implementation of the Amended Arrangement is subject to obtaining the final order of the Court, approvals from Shareholders at the Meeting, Canadian Securities Exchange approval, and satisfaction of certain other conditions to implementing the Amended Arrangement as set forth in the proposal agreement dated June 24, 2020 between Acreage and Canopy Growth.

07:33 EDT Cytokinetics announces four-year partnership with HCM Registry - Cytokinetics announced a $1M grant and four-year partnership with the HCM Registry, a global registry of patients with hypertrophic cardiomyopathy focused on improving predictive measures of risk for complications and identifying biomarkers associated with adverse clinical outcomes. The HCMR was designed as the first prospective multinational registry to identify novel prognostic markers in HCM, including CMR markers of fibrosis, genetic markers, and biomarkers. It has been funded to date by the National Heart, Lung, and Blood Institute, part of the National Institutes of Health and is being conducted by the University of Virginia and the University of Oxford. As an industry sponsor, Cytokinetics will join the HCMR Steering Committee in an observational capacity. The HCMR is a prospective, observational study that enrolled 2,755 participants from 44 sites in six countries in North America and Europe who will be followed for at least five years and up to 10. Enrollment began in 2014 and completed in 2017. Primary outcome measures include cardiac death, aborted sudden cardiac death, heart transplant and left ventricular assist device placement. Secondary outcome measures include all-cause mortality, ventricular tachyarrhythmias, hospitalization for heart failure, atrial fibrillation and stroke. The results of the study will help predict the risk of developing complications associated with HCM and provide evidence to inform better treatment decisions.

07:32 EDT Shyft Group is producing its first order of electric vehicles - The Shyft Group announced its Utilimaster brand is producing its first production order of electric vehicles, or EV, for two leading parcel delivery companies on its new flexible body assembly line. Utilimaster has proven EV walk-in vans on the road today with linen and uniform delivery customers, but these new orders represent the first EV walk-in vans designed specifically for, and ordered by, its parcel fleet customers. The vehicles are built upon Shyft's traditional walk-in van chassis platform, which has been converted to use an all-electric powertrain. The EVs will be evaluated by these customers for route testing, suitability, and performance, and the feedback from these units will be used to further refine the features of Shyft's electric last mile delivery vehicles. Production of the electric delivery vehicles is expected to begin in 2021 with a dedicated EV chassis assembly line that can produce up to 5,000 units per year on a single shift.

07:14 EDT Natural Gas Services sees 2H20 capex $8M-$10M - Forecasted capital expenditures of $8M-$10M for the second half of 2020 backed by recent rental order that will require $6+M in capital.

07:12 EDT CSI Compressco regains compliance with Nasdaq listing rules - CSI Compressco announced that it received a letter from the Nasdaq Stock Marke on August 17 which contained a NASDAQ compliance determination that the Partnership has regained compliance with NASDAQ Listing Rule 5450, which requires listed securities to maintain a minimum closing bid price of $1.00 per unit. CSI Compressco's common units have maintained a closing bid price of at least $1.00 per unit for more than ten consecutive trading days. Accordingly, CSI Compressco has regained compliance with Nasdaq Listing Rule 5450 and Nasdaq considers the prior bid price deficiency matter now closed.

07:08 EDT Canadian Solar subsidiary begins construction of Pflugerville Solar Project - Canadian Solar announced its wholly-owned subsidiary, Recurrent Energy, commenced construction on the 144 MWac Pflugerville Solar Project located in Travis County, Texas. Recurrent Energy signed a Power Purchase Agreement, or PPA, with Austin Energy in 2018 for the Pflugerville Solar Project to provide low-cost solar power to the utility's customers for 15 years following the start of operation. This PPA supports Austin Energy's renewable energy goals which commit the utility to cost-effectively reduce emissions and includes plans to exit from its coal-fired power generation by the end of 2022. The Pflugerville Solar Project is expected to create long-term permanent jobs to support the operation and maintenance of the power plant, as well as more than 350 construction jobs of which at least 50% will be performed by local workers. The project will also have a positive economic impact on the local community by providing tax revenues for Travis County and the Elgin ISD, which will total approximately $350M throughout the life of the project. Once operational, the Pflugerville Solar Project is expected to generate enough low-cost clean electricity to power the equivalent of approximately 25,000 Texas homes.

07:06 EDT MICT, Inc.: Micronet receives first major order for SmartCam - MICT, Inc. announced that its subsidiary Micronet Ltd. has received the first significant order for its new, highly innovative video telematics product, SmartCam, which integrates advanced software and AI functionality to serve the fastest growing segment of the estimated $45B global telematics market. SmartCam, which received U.S. Federal Communications Commission authorization for 2.4GHZ, 5GHZ and LTE, subsequently entered a pilot trial with a global telematics provider, an ongoing customer of Micronet, leading to this first substantial order for SmartCam in the North American market.

07:06 EDT Walmart incurred incremental costs related to COVID-19 of $1.5B

07:04 EDT Vanda Pharmaceuticals: Tradipitant may accelerate improvement in COVID-19 - Vanda Pharmaceuticals reported that interim analysis showed tradipitant may accelerate clinical improvement in SARS-CoV-2 (COVID-19) pneumonia in the ODYSSEY study. Interim analysis of the ODYSSEY study showed that a 14 day tradipitant treatment accelerated clinical improvement by day 7. Tradipitant numerically improved median time to clinical improvement by day 28. Similar overall rates of improvement and mortality were observed for the two treatment arms at day 28. The interim analysis of the ODYSSEY study demonstrated that hospitalized patients with COVID-19 pneumonia improved sooner when treated with tradipitant as compared to placebo. This finding was based on a preliminary analysis of the first 60 patients enrolled in the ODYSSEY study of tradipitant in COVID-19 pneumonia. ODYSSEY is an ongoing Phase III double-blind placebo-controlled trial investigating the efficacy and safety of tradipitant, a neurokinin-1 receptor antagonist, in the treatment of neurogenic inflammation of the lung secondary to SARS-CoV-2 (COVID-19) infection, which was initiated in April 2020. The study is expected to enroll 300 patients, and as of July 15, 2020, 60 patients had enrolled and completed the study. Because this is the first study of tradipitant for this indication and given the increased rate of mortality seen with COVID-19 pneumonia, an interim analysis was planned to better assess the efficacy and safety of tradipitant in this population of COVID-19 patients.

07:04 EDT Walmart jumps 6% in pre-market trading after Q2 earnings beat estimates

07:01 EDT Taiwan announces plans to ban iQIYI, Tencent streaming services - Taiwan plans to ban iQIYI (IQ) and Tencent (TCEHY) streaming services, Bloomberg reports, citing a statement from the Taiwan Economic Affairs Ministry. The Taiwanese government will issue a formal order on September 3 to forbid individuals and entities in Taiwan to license or distribute the two Chinese companies' streaming services, according to Bloomberg. IQiyi did not win approval from the government to operate a streaming service when it applied to set up a subsidiary in Taiwan in 2016, the statement says. Reference Link

06:58 EDT Johnson Controls CFO Brian Stief to retire, Olivier Leonetti to succeed - Johnson Controls (JCI) announced that Olivier Leonetti would join the company and succeed Brian Stief as the CFO. Leonetti will join the company in the next several weeks and initially be appointed as executive VP and CFO-elect. He will assume the role of executive VP and CFO, following the filing of the company's annual report on Form 10-K for FY20. Current vice chairman and CFO Brian Stief, will step down from the CFO role at that time. Stief will remain in his role as vice chairman, serving in an advisory capacity, and will retire from the company at the end of this calendar year. Stief and Leonetti will work closely together over the next several months to ensure an orderly transition into the 2021 calendar year. Most recently, Leonetti served as senior vice president, CFO for Zebra Technologies (ZBRA). With responsibility for over 1000 employees, Leonetti managed all finance and IT functions, including investor relations and global business services.

06:50 EDT Biolase promotes CFO John Beaver to COO, will retain prior role - Biolase announced that John Beaver, the company's CFO since 2017, has been promoted to the newly-created role of COO. Beaver will retain his responsibilities as CFO and will continue to work closely with Todd Norbe, president and CEO of the company, to execute its growth strategy.

06:47 EDT Store Capital announces August rent collections of 86% - STORE Capital Corporation (STOR) announced August rent collections and the repayment of the majority of borrowings on its credit facility. As of August 17, STORE Capital had received rent payments representing 86% of contractual base rent and interest for the month of August. July collections also increased to 86%, up from the previously announced 85%. Based on an updated survey of STORE Capital tenants, the percentage of properties open in August also increased to 93% from 92% in July. "The number of our locations open for business has continued to increase since May, and rent collections have risen accordingly," said Christopher Volk, President and CEO. "During August, no new tenants requested lease deferrals. Moreover, the high level of rent collections and the consistency of our portfolio performance have given us the confidence to repay $450M of borrowings on our credit facility, returning our borrowings on the credit facility to pre-COVID levels. As our tenants have been able to conduct commerce, STORE has predictably realized elevated rental income, which we believe will continue as more locations are able to reopen. We are also gratified that the confidence in our tenants and business model has been recognized by our stockholders. Notably, Berkshire Hathaway (BRK.A) increased its ownership of STORE Capital by 31%, to nearly 10% of shares outstanding as of June 30."

06:39 EDT Eli Lilly, Innovent announce global expansion of TYVYT licensing agreement - Eli Lilly and Innovent Biologics announced a global expansion of their strategic alliance for TYVYT, an anti-PD-1 monoclonal antibody immuno-oncology medicine that was co-developed by Innovent and Lilly in China. In 2019, Lilly and Innovent began commercializing TYVYT in China after being granted marketing approval for relapsed or refractory classic Hodgkin's lymphoma after at least two lines of systemic chemotherapy. TYVYT is the only PD-1 inhibitor to be included in China's National Reimbursement Drug List, or NRDL, and is included in the 2019 Guidelines of Chinese Society of Clinical Oncology for Lymphoid Malignancies. Lilly and Innovent currently co-commercialize TYVYT in China. Under the terms of the expanded license agreement, Lilly will obtain an exclusive license for TYVYT for geographies outside of China and plans to pursue registration of TYVYT in the U.S. and other markets. In return, Innovent will receive an upfront payment of $200M and will be eligible for up to $825M in potential development and commercial milestones, as well as tiered double-digit royalties on net sales. Both companies will also retain the right to study TYVYT in combination with other medicines as part of their own clinical programs. The two companies are also studying TYVYT as a potential therapy in non-squamous non-small cell lung cancer, or NSCLC, and several other types of cancer. Earlier this month, the two companies released interim analysis data from ORIENT-11 at the IASLC World Conference on Lung Cancer Virtual Presidential Symposium. ORIENT-11 is a randomized, double-blind, Phase 3 clinical trial evaluating TYVYT or placebo in combination with Alimta and platinum chemotherapy as a first-line treatment for advanced or recurrent non-squamous NSCLC without sensitizing EGFR mutations or ALK rearrangements. Based on the interim analysis conducted by the Independent Data Monitoring Committee, TYVYT in combination with Alimta and platinum chemotherapy demonstrated a statistically significant improvement in progression-free survival compared with placebo in combination with Alimta and platinum chemotherapy, which met the pre-defined efficacy criteria. A supplemental new drug application, or sNDA, for this indication is under regulatory review in China. The companies said they look forward to future submissions with the FDA and other regulatory agencies for this and other indications. This transaction is subject to customary closing conditions, including clearance under the Hart-Scott-Rodino Antitrust Improvements Act. The transaction will be reflected in Lilly's reported results and financial guidance according to Generally Accepted Accounting Principles. There will be no change to Lilly's 2020 non-GAAP earnings per share guidance as a result of this transaction.

06:36 EDT Kingsoft Cloud sees Q3 revenue up 67%-74% from last year - For the Q3, the Company expects total revenues to be between RMB1.67B-RMB1.74B, representing a year-over-year growth of 67%-74%. This forecast reflects the Company's current and preliminary views on the market and operational conditions, which are subject to change.

06:34 EDT Advance Auto Parts seeing 'strong growth' in DIY Omnichannel in Q3 - AAP said, "Through the first five weeks of the third quarter, the company continues to see strong growth in DIY Omnichannel and positive comparable store sales in Professional. While uncertainties remain around the continued impact of COVID-19 during the balance of the year, the company believes it is well positioned to meet the demands of the business."

06:19 EDT National Health Investors provides business update on collections, occupancy - National Health Investors provided a business update regarding its monthly contractual rent collections and average occupancy from its three largest senior housing operators. NHI collected 95.3% of contractual rent in August and deferred 4.2% including 2.5% related to a previously disclosed deferral to Bickford. The remaining balance relates to forecasted revenue the company had expected to receive from transitioned properties prior to the start of the pandemic. NHI collected 96.9% of contractual rent in July and 100% in Q2. The following table summarizes the average portfolio occupancy for Bickford, Holiday and SLC for the periods indicated, excluding development properties in operation less than 24 months, notes receivable, and properties transitioned to new operators or disposed. Bickford same-store occupancy excludes properties that have been operated by Bickford for less than 24 months. The information in the table below is based upon information provided to us by our operators.

06:04 EDT Amazon.com confirms plans to create 3,500 new jobs in six U.S. cities - Amazon announced plans to create 3,500 new tech and corporate jobs across six cities in the United States. The company will expand its Tech Hubs in Dallas, Detroit, Denver, New York (Manhattan), Phoenix, and San Diego. Amazon will invest more than $1.4B in these new offices, which will host teams supporting businesses across the company.

06:02 EDT Halliburton awarded contract by PTTEP - PTTEP awarded Halliburton a contract to design and implement a series of digital transformation projects as part of PTTEP's Advanced Production Excellence, or APEX, Initiative. APEX will improve operational efficiency and production in four offshore fields: Arthit, Greater Bongkot South, Greater Bongkot North and the Myanmar Zawtika Field. Landmark, a Halliburton business line, will deploy its DecisionSpace Production Suite in the cloud to improve production operations from the subsurface to processing facilities. The DecisionSpace Enterprise Platform will integrate with Honeywell Forge, a powerful analytics software solution providing real-time data and visual intelligence, so PTTEP can implement more productive and efficient work processes.

05:54 EDT CooTek names Robert Cui as CFO, effective August 24 - Prior to joining CooTek, Cui worked in the Hong Kong office of Investment Banking Asia Pacific of BNP Paribas from 2014 to 2020 with his last position held as a director.